Exclusive: Houston startup rebrands to provide AI chat tool focused on women’s health

meet ema

A Houston founder is introducing you to ema — a GPT-based chat platform and your new best friend in women's health. Photo via Canva

Amanda Ducach set out to create a platform where mothers could connect with each other socially, but when she launched SocialMama just ahead of a global pandemic, she soon learned there was a bigger market need for access to information surrounding women's health — from fertility to menopause.

After pivoting her femtech platform to include women's health experts, she realized her technology wasn't able to completely support growing user base. The platform, which was called SocialMama, saw users engaging with experts in similar ways — and as Ducach looked into growing the platforms users, she realized that 24/7 access to experts was going to be hard to scale.

"We noticed that most of these conversations were repetitive," Ducach tells InnovationMap. "You had women asking an expert about tracking ovulation a hundred times a day. Having an OBGYN answer that question a hundred times a day was crazy and just not scalable."

Ducach says that about 16 months ago, her team took a step back to recreate the platform incorporating GPT technology. GPT stands for generative pre-trained transformer, and is a family of artificial intelligence language models most recently made popular but ChatGPT developed by OpenAI.

Now, after building out the platform, Ducach's company has rebranded to ema. The AI-based chat tool — named from the three letters in the middle of "female" — is meant to feel like texting "your childhood best friend who became an OBGYN physician," Ducach says. Not only can the chat provide crucial medical information, but it has a memory and can pick up conversations where they left off to be a constant resource to users.

The new platform, deemed ema, operates as an AI-based chat for women to engage with. Screenshot courtesy of ema

"Ema can answer everything from, 'how do I improve my baby's latch,' to 'how to I get a diabetic-friendly brownie recipe,' to 'give me an affirmation that's spoken like Snoop Dog because I'm feeling sad today,'" Ducach says.

Ducach first described the evolution of the company to AI-based communication last summer on the Houston Innovators Podcast. Now, the platform is gearing up for its launch next month and plans to raise seed funding this year to double her current team of 10 people to support the company's growth. Ducach, who was accepted into the Techstars Austin program in 2021, also says she's looking for more beta users in the meantime, and those interested should reach out to her or her team.

Ultimately, Ducach says the mission of ema is to democratize access to women's health care so that women feel supported and just a few taps away from important information.

"Barriers to care for women who face socioeconomic disparities is where you see the need for change," Ducach says. "For us, it's reducing those barriers of care. Ema is always in your pocket. You have access to her 24/7. The way that ema is really structured and her purpose is to catch red flags so that we can then help the female user get to positive health outcomes."

Amanda Ducach founded the company in 2019. Photo via Twitter

From Your Site Articles
One way to move the needle on developing femtech, according to this expert, is to make sure women have a seat at the table at venture firms funding the innovations. Photo via Getty Images

The growing femtech industry needs more attention — and funds, says this Houston expert

guest column

Femtech is a term that is generally given to medical products, software, and technologies that aim to enhance the health and wellbeing of women. But when people think of femtech, things like period tracker apps and pregnancy tests are usually the first things to come to mind. While those developments are important and used regularly, there are other diseases and chronic issues affecting women that need to be talked about as well.

The concept of femtech shouldn't replace "women's health" which considers broader issues, such as endometriosis and PCOS, as well as other conditions — such as heart disease — common to both men and women but clinically different in the latter. Femtech investors, manufacturers, and health advocates should focus on creating solutions for all issues and diseases that affect women, not just the most obvious.

However, more education and awareness is necessary to bring these issues to the forefront, as many people are not aware about how certain chronic issues and diseases affect women differently than they may affect men. For example, heart disease is the leading cause of death in women and men, but if you close your eyes and envision someone having a heart attack — do you see a man? Or a woman? Probably a man. And you're not alone. Because so much of our healthcare research has focused primarily on men, we are programmed to think of certain conditions affecting men predominantly when they are truly major health issues for both.

Similarly, when it comes to memory loss, women have a 1 in 5 chance of developing Alzheimer's disease compared to men being 1 in 11. Additionally, out of the more than 5 million people living with Alzheimer's in the U.S., 3.2 million are women. While there aren't as many Femtech-related products or solutions focused on these issues, there should be, especially in a rapidly growing industry.

According to the U.S. Clinical Laboratory Test Market, the femtech industry is expected to grow at a compound annual growth rate of more than 13 percent. Frost and Sullivan predicts the global Femtech market revenue will reach $1.1 billion by 2024, and BIS Research forecasts that by 2030 the sector will hit $3.04 billion. But even with great momentum, there is a knowledge gap that needs to be bridged. Overall, the industry has been underfunded and many opportunities have been overlooked, not necessarily because of gender. But, because investors in the industry are predominantly men, there is a lack of education and understanding of why these products are needed.

A solution would be for more women to become investors. Women have the personal experience and a better understanding of how these products will benefit them, which allows them to better understand the story told, increasing the chance the product will be funded and brought to market. To fund life-changing inventions for women, we need to have women involved, which means we need women to step into the investment community. Until more women get a seat at the investment table, women in femtech who are looking for investors need to be prepared to share real life stories and provide as much information as possible to have a better chance of securing funding.

The femtech industry is growing, and we will continue to see innovative devices and apps brought to market. With more education, a better understanding of other issues that affect women, and more female investors, the industry has the potential to take its growth to a new level.

------

Isabella Schmitt currently serves as the director of regulatory affairs at Proxima Clinical Research Inc.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston students develop cost-effective glove to treat Parkinson's symptoms

smart glove

Two Rice undergraduate engineering students have developed a non-invasive vibrotactile glove that aims to alleviate the symptoms of Parkinson’s disease through therapeutic vibrations.

Emmie Casey and Tomi Kuye developed the project with support from the Oshman Engineering Design Kitchen (OEDK) and guidance from its director, Maria Oden, and Rice lecturer Heather Bisesti, according to a news release from the university.

The team based the design on research from the Peter Tass Lab at Stanford University, which explored how randomized vibratory stimuli delivered to the fingertips could help rewire misfiring neurons in the brain—a key component of Parkinson’s disease.

Clinical trials from Stanford showed that coordinated reset stimulation from the vibrations helped patients regain motor control and reduced abnormal brain activity. The effects lasted even after users removed the vibrotactile gloves.

Casey and Kuye set out to replicate the breakthrough at a lower cost. Their prototype replaced the expensive motors used in previous designs with motors found in smartphones that create similar tiny vibrations. They then embedded the motors into each fingertip of a wireless glove.

“We wanted to take this breakthrough and make it accessible to people who would never be able to afford an expensive medical device,” Casey said in the release. “We set out to design a glove that delivers the same therapeutic vibrations but at a fraction of the cost.”

Rice’s design also targets the root of the neurological disruption and attempts to retrain the brain. An early prototype was given to a family friend who had an early onset of the disease. According to anecdotal data from Rice, after six months of regularly using the gloves, the user was able to walk unaided.

“We’re not claiming it’s a cure,” Kuye said in the release. “But if it can give people just a little more control, a little more freedom, that’s life-changing.”

Casey and Kuye are working to develop a commercial version of the glove priced at $250. They are taking preorders and hope to release 500 pairs of gloves this fall. They've also published an open-source instruction manual online for others who want to try to build their own glove at home. They have also formed a nonprofit and plan to use a sliding scale price model to help users manage the cost.

“This project exemplifies what we strive for at the OEDK — empowering students to translate cutting-edge research into real-world solutions,” Oden added in the release. “Emmie and Tomi have shown extraordinary initiative and empathy in developing a device that could bring meaningful relief to people living with Parkinson’s, no matter their resources.”

New Austin tower eclipses Houston landmark as Texas' tallest building

Tallest in Texas

Texas officially has a new tallest tower. The title moves from Houston, for the JPMorgan Chase Tower, to Austin, for Waterline at 98 Red River St. The new tower will contain mixed-use spaces including apartments, offices, a hotel, restaurants, and retail. It is scheduled to open in full in 2026.

Waterline held a "topping out" ceremony in August, when the final beam was added to the top of the tower. It now reaches 74 stories and 1,025 feet — just 23 feet taller than the JPMorgan Chase Tower.

Waterline height comparison Waterline is now the tallest building in Texas.Graphic courtesy of Lincoln Property Company

According to a press release, hundreds of construction workers and team project members attended the Waterline ceremony, and more than 4,750 people have worked on it since the project broke ground in 2022. An estimated 875 people were working onsite every day at the busiest time for construction.

The Waterline site is on a 3.3-acre campus with lots of views of Waller Creek and Lady Bird Lake. The building contains space for 352 luxury apartments, 700,000 square feet of offices, a hotel called 1 Hotel Austin with 251 rooms, and 24,000 square feet of retail stores and restaurants.

The only space that is open to new tenants already is the office space, with residential soon to follow. The hotel and residential units are expected to open in fall 2026.

Waterline tower Austin A view from above, shot by drone.Photo courtesy of Lincoln Property Company and Kairoi Residential

“Seamlessly integrated with Waller Creek, Waterloo Greenway and the hike-and-bike trail around Lady Bird Lake, Waterline will quickly become a top downtown destination and activity center," said Lincoln executive vice president Seth Johnston in a press release. Project improvements will also make it far easier for people to access all of the public amenities in this area from Rainey Street, the new Austin Convention Center, and the rest of the Central Business District."

---

This article originally appeared on CultureMap.com.

Houston company awarded $2.5B NASA contract to support astronaut health and space missions

space health

Houston-based technology and energy solution company KBR has been awarded a $2.5 billion NASA contract to support astronaut health and reduce risks during spaceflight missions.

Under the terms of the Human Health and Performance Contract 2, KBR will provide support services for several programs, including the Human Research Program, International Space Station Program, Commercial Crew Program, Artemis campaign and others. This will include ensuring crew health, safety, and performance; occupational health services and risk mitigation research for future flights.

“This contract reinforces KBR’s leadership in human spaceflight operations and highlights our expertise in supporting NASA’s vision for space exploration,” Mark Kavanaugh, KBR president of defense, intel and space, said in a news release.

The five-year contract will begin Nov. 1 with possible extension option periods that could last through 2035. The total estimated value of the base period plus the optional periods is $3.6 billion, and the majority of the work will be done at NASA’s Johnson Space Center.

“We’re proud to support NASA’s critical work on long-duration space travel, including the Artemis missions, while contributing to solutions that will help humans live and thrive beyond Earth,” Kavanaugh adde in the news release.

Recently, KBR and Axiom Space completed three successful crewed underwater tests of the Axiom Extravehicular Mobility Unit (AxEMU) at NASA's Neutral Buoyancy Laboratory (NBL) at Johnson Space Center. The tests were part of an effort to help both companies work to support NASA's return to the Moon, according to a release.

KBR also landed at No. 3 in a list of Texas businesses on Time and Statista’s new ranking of the country’s best midsize companies.

View All Listings